A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors, Trial ID 1948-CL-0101

Study summary

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab.

Additional Study Details

Phase

Phase 1

Product

ASP1948

Product

ASP1948

nivolumab

pembrolizumab

Type

Interventional

Masking

None (Open Label)

Enrollment number

190

Show Additional Study Details

Study documents

Scientific Results Summary

Available Language(s): English

Download Document(s)

Plain Language Summary

Available Language(s): English

Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors? Contact us by filling out your information to the right and we’ll respond to you.

Requestor Information [I am…]

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

First name

Last Name

Country/Region

Algeria
Argentina
Armenia
Australia
Austria
Belarus
Belgium
Bosnia And Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Finland
Former Serbia and Montenegro
France
Georgia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Latvia
Lebanon
Lithuania
Macedonia
Malaysia
Mexico
Montenegro
Morocco
Netherlands
New Zealand
Norway
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Turkey
Ukraine
United Kingdom
United States
Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Completed

Norton Cancer Institute

Louisville, KY, United States, 40202

Completed

Site TW88602

Taipei, Taiwan, Province of China

Completed

Oncology Hematology West P.C. dba Nebraska Cancer Specialists

Omaha, NE, United States, 68310

Completed

Site KR82002

Seoul, Republic of Korea

Completed

Washington University

St. Louis, MO, United States, 63110

Withdrawn

University of Chicago

Chicago, IL, United States, 60637

Completed

Site KR82005

Seoul, Republic of Korea

Completed

Mary Crowley Cancer Research Center

Dallas, TX, United States, 75230

Completed

Site KR82004

Seoul, Republic of Korea

Completed

Comprehensive Cancer Centers of Nevada

Las Vegas, NV, United States, 89169

Withdrawn

University of Tennessee Medical Center

Knoxville, TN, United States, 37920

Withdrawn

Montefiore Medical Center

Bronx, NY, United States, 10461

Completed

Virginia Cancer Care Specialist, PC

Fairfax, VA, United States, 22031

Completed

Henry-Joyce Cancer Center

Nashville, TN, United States, 37232

Withdrawn

Site CA15001

Toronto, Canada

Withdrawn

Memorial Sloan Kettering Cancer Center

New York, NY, United States, 10065

Completed

Cancer Center at Greater Baltimore Medical

Baltimore, MD, United States, 21153

Completed

University of Washington-Seattle Cancer Care Alliance

Seattle, WA, United States, 98109

Completed

Icahn School of Medicine at Mount Sinai

New York, NY, United States, 10029

Completed

Site KR82001

Seoul, Republic of Korea

Completed

Site CA15004

Montreal, Canada

Completed

University of Oklahoma

Oklahoma City, OK, United States, 73104

Completed

University of Michigan Comprehensive Cancer Center

Ann Arbor, MI, United States, 48109

Completed

Sarah Cannon Research Institute – SCRI

Nashville, TN, United States, 37203

Withdrawn

Froedtert & The medical college of Wisconsin

Milwaukee, WI, United States, 53226

Withdrawn

Oregon Health and Science University

Portland, OREGON, United States, 97239

Withdrawn

The Ohio State University James Cancer Hospital and Solove Research Institute

Columbus, OH, United States, 43210

Completed

Site KR82006

Seoul, Republic of Korea

Completed

Site KR82003

Seoul, Republic of Korea

Completed

Yale Center for Clinical Investigation

New Haven, CT, United States, 06520-8028

Withdrawn

Augusta University

Augusta, Georgia, United States, 30912

Completed

UPMC- Hillman Cancer Center

Pittsburgh, PA, United States, 15232

Completed

Site KR82007

Seoul, Republic of Korea

Completed

University of South Carolina

Charleston, SC, United States, 29425

Withdrawn

Dartmouth Hitchcock Med Center

Lebanon, New Hampshire, United States, 03756

Completed

South Texas Accelerated Research Therapeutics

San Antonio, TX, United States, 78229

Completed

Site CA15002

Edmonton, Canada

Withdrawn

Women And Infants

Providence, RI, United States, 02905

Withdrawn

Site ES34001

Avila, Spain

Completed

Site ES34003

Cataluna, Spain

Completed

Site ES34004

Cataluna, Spain

Withdrawn

Site ES34005

Valencia, Spain

Completed

Site ES34007

Madrid, Spain

Withdrawn

Site ES34009

Madrid, Spain

Completed

Site ES34012

Madrid, Spain

Withdrawn

Site GB44001

Glasgow, United Kingdom

Completed

Site TW88601

Taipei, Taiwan, Province of China

Completed

Site ES34010

Barcelona, Spain

Completed

Site JP81001

Tokyo, Japan

Completed

Site JP81002

Chiba, Japan

Completed

Site IT39006

Modena, Italy

Completed

Site IT39008

Milano, Italy

Withdrawn

Site IT39003

Meldola, Italy

Completed

Site ES34002

Barcelona, Spain

Withdrawn

Huntsman Cancer Institute

Salt Lake City, Utah, United States, 84112

Completed

Site ES34006

Barcelona, Spain

Completed

Site ES34014

Barcelona, Spain

Withdrawn

Site CA15006

Toronto, Canada

Withdrawn

Site IT39001

Monza, Italy

Withdrawn

Site IT39005

Milano, Italy

Withdrawn

Site IT39007

Milano, Italy

Completed

Site PT35104

Porto, Portugal

Withdrawn

Site PT35105

Braga, Portugal

Withdrawn

Site GB44003

Sheffield, United Kingdom

Withdrawn

Site GB44004

Newcastle upon Tyne, United Kingdom

Completed

Site GB44006

Manchester, United Kingdom

Withdrawn

Mayo clinic

Phoenix, AZ, United States, 85259

Withdrawn

Site TW88603

Tainan, Taiwan, Province of China

Withdrawn

Henry Ford Health System

Detroit, MI, United States, 48202

Trial info

Follow Trial

Age

18+ years

Condition

Advanced/Metastatic Cancer

Sex

Female & Male

Trial Dates

Jul 2018 - Mar 2023

Share with

Additional Study Details

Inclusion Criteria

Subject has locally-advanced (unresectable) or metastatic solid tumor malignancy (no limit to the number of prior treatment regimens) that is confirmed by available pathology records or current biopsy, and has received all standard therapies (unless the therapy is contraindicated or intolerable) felt to provide clinical benefit.
Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1.
Subject’s last dose of prior antineoplastic therapy, including any immunotherapy, was at least 21 days prior to initiation of study drug administration. A subject with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation-positive NSCLC is allowed to remain on EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor therapy until 4 days prior to the start of study drug administration.
Subject has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to study drug administration.
Subject with metastatic castration-resistant prostate cancer (mCRPC) (positive scan and/or soft tissue disease documented by computed tomography/magnetic resonance imaging) meets both of the following:
- Subject has serum testosterone ≤ 50 ng/dL at screening.
- Subject has had an orchiectomy or plans to continue androgen deprivation therapy (ADT) for the duration of study treatment.
Subject has adequate organ function as indicated by laboratory values. (If a subject has received a recent blood transfusion, the laboratory tests must be obtained ≥ 28 days after any blood transfusion.) Subjects can be on a stable dose of erythropoietin (≥ approximately 3 months). Note: Growth factors, colony stimulating factors are not permitted in the screening period.
Female subject must either:
- Be of non-childbearing potential: post-menopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or; documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
- Or, if of childbearing potential: Agree not to try to become pregnant during the study treatment and for 6 months after the final study drug administration; and have a negative urine or serum pregnancy test prior to study drug administration; and if heterosexually active, agree to consistently use 1 form of highly effective birth control starting at screening and throughout the study treatment and 6 months after the final study drug administration.
Female subject must agree not to breastfeed starting at screening and throughout the study treatment, and for 6 months after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study treatment, and for 6 months after the final study drug administration.
A sexually active male subject with female partner(s) who are of childbearing potential is eligible if :
- The male subject agrees to use a male condom starting at screening and continues throughout the study treatment, and for 6 months after the final study drug administration.
- The male subject has not had a vasectomy or is not sterile, as defined below and the subject's female partner(s) is utilizing 1 form of highly effective birth control starting at screening and continuing throughout the study treatment and for 6 months after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study treatment, and for 6 months after the final study drug administration.
Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study treatment and for 6 months after the final study drug administration.
Subject agrees not to participate in another interventional study while receiving study drug (subjects who are currently in the follow-up period of an interventional clinical trial are allowed).

Additional Inclusion Criteria for Subjects in the Expansion Cohorts:

Subject has at least 1 measurable lesion per RECIST 1.1. The measureable lesion must be outside the field of radiation if subject had prior radiotherapy. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Subjects with mCRPC who do not have measurable lesions must have at least 1 of the following:
- Progression with 2 or more new bone lesions, or
- Prostate specific antigen (PSA) progression (defined as a minimum of 3 rising PSA levels with an interval of ≥ 1 week between each determination) within 6 weeks prior to study drug administration and a PSA value at the screening visit ≥ 2 ng/mL.
Subject consents to provide available tumor specimen in a tissue block or unstained serial slides obtained within 8 to 56 days prior to first dose of study treatment. Note: This does not apply to subjects with mCRPC who do not have measurable disease.
Subject is an appropriate candidate for tumor biopsy and consents to undergoing a tumor biopsy (core needle biopsy or excision) during the treatment period. Note: This does not apply to subjects with mCRPC who do not have measurable disease.
Subject meets one of the following:
- Subject has the tumor type for which a confirmed response was observed in a monotherapy or in combination with nivolumab dose escalation or RP2D cohort; or
- ASP1948 monotherapy or in combination with pembrolizumab expansion cohort is opened due to achieving predicted efficacious exposure, subject has squamous cell carcinoma of the head and neck (SCCHN); or
- RP2D monotherapy cohort is opened and subject has NSCLC, mCRPC, ovarian cancer, pancreatic cancer or breast cancer; or
- o RP2D combination with pembrolizumab expansion cohort, is opened and subject has NSCLC (all PD-L1 status), NSCLC PD-L1 high*, ovarian cancer, colorectal cancer, or breast cancer.

*NSCLC with PD-L1 high expressing tumor as determined by immunohistochemistry at a central laboratory during the screening period.

Additional Inclusion Criteria for Re-treatment:

Subjects may be eligible for study drug re-treatment if the study remains open and the subject continues to meet all of the eligibility criteria above (except prior use of this drug) and the following conditions:

Subject stopped initial treatment with ASP1948 or ASP1948 in combination with nivolumab or pembrolizumab after attaining a confirmed CR or PR or SD.
Subject experienced a confirmed disease progression by iRECIST (iCPD) after stopping their initial treatment with ASP1948 or ASP1948 in combination with nivolumab or pembrolizumab.
Subject did not receive any prohibited anti-cancer treatment since the last dose of ASP1948 or ASP1948 in combination with nivolumab or pembrolizumab.
Subject did not experience a toxicity that met the discontinuation criteria during the initial treatment with ASP1948 or ASP1948 in combination with nivolumab or pembrolizumab.

Exclusion Criteria

Subject weighs < 45 kg.
Subject has received investigational therapy (other than an investigational epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in a subject with EGFR mutations or ALK inhibitor in a subject with an ALK mutation) within 21 days prior to start of study drug.
Subject requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study drug administration. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent(defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone or up to 10 mg per day of prednisone) are allowed. Note: Corticosteroids for prophylaxis (e.g., contrast dye allergy) or for brief treatment of conditions not related to study treatment (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is also allowed.
Subject has symptomatic central nervous system (CNS) metastases or subject has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Subjects with previously treated CNS metastases are eligible, if the subject is clinically stable and has no evidence of CNS progression by imaging for at least 28 days prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone, > 2 mg per day of dexamethasone or > 10 mg per day of prednisone or equivalent) for longer than 14 days.
Subject has leptomeningeal disease as a manifestation of the current malignancy.
Subject has an active autoimmune disease that has required systemic treatment in the past 2 years. Subjects with type 1 diabetes mellitus, stable endocrinopathies maintained on appropriate replacement therapy and skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed.
Subject was discontinued from prior immunomodulatory therapy due to a Grade ≥ 3 toxicity that was mechanistically related (e.g., immune related) to the agent.
Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP1948, nivolumab or pembrolizumab or severe hypersensitivity reaction to treatment with another monoclonal antibody.
Subject with positive Hepatitis B virus antibodies and surface antigen (indicating acute Hepatitis B virus (HBV) or chronic HBV) or Hepatitis C (HCV ribonucleic acid (RNA) [(qualitative or quantitative)]. Hepatitis C RNA testing is not required in subjects with negative Hepatitis C antibody testing. Hepatitis B virus antibodies are not required in subjects with negative Hepatitis B surface antigen.
Subject has received a live vaccine against infectious diseases within 28 days prior to initiation of study treatment.
Subject has a history of drug-induced pneumonitis (interstitial lung disease), a history of (non-infectious) pneumonitis that required steroids, radiation pneumonitis or currently has pneumonitis.
Subject has an active infection requiring systemic therapy within 14 days prior to study drug treatment.
Subject is expected to require another form of antineoplastic therapy while on study treatment.
Subject has an uncontrolled intercurrent illness including, but not limited to cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.
Subject’s AEs (excluding alopecia) from prior therapy have not improved to Grade 1 or baseline within 14 days prior to start of study treatment.
Subject has significant cardiovascular disease including:
- Subject has inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
- Subject has a history of myocardial infarction or unstable angina within 6 months prior to day 1.
- Subject has New York Heart Association Class II or greater chronic heart failure (CHF).
- History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to study treatment.
- Subject has significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study treatment.
Subject has a history of hemoptysis (bright red blood of ½ teaspoon or more per episode) within 12 weeks prior to study treatment.
Subject has evidence of a bleeding diathesis or significant coagulopathy.
Subject has inadequate recovery from prior surgical procedure or has had a major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1, or anticipates the need for a major surgical procedure during the course of the study or minor surgery within 7 days of starting study treatment.
Subject has initiated new treatment with medications that affect the coagulation cascade with an international normalized ratio (INR) ≥ 2 such as vitamin K antagonists, heparins and direct thrombin inhibitors or the use of factor Xa inhibitors within 28 days prior to the start of study treatment. Note: If the subject started receiving such medications more than 28 days prior to the start of study treatment and needs to continue, this is allowed. However, new anticoagulation may not be initiated within 28 days prior to the start of study treatment.
Subject has any condition that makes the subject unsuitable for study participation.
Subject has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
Subject has had an allogeneic tissue solid organ transplant.
Subject has known history of COVID-19 positive polymerase chain reaction (PCR) test within 4 weeks prior to start of study treatment.

Additional Exclusion Criteria for Subjects in Expansion Cohorts:

Subject has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for locally curable malignancies that have been apparently cured, which are allowed, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
Subject has received prior treatment with a neuropilin-1 (NRP1) inhibitor.

Additional Exclusion Criteria for Re-treatment:

Subjects who have completed 40 weeks (ASP1948 monotherapy or combination therapy with nivolumab cohorts) or 57 weeks (ASP1948 combination therapy with pembrolizumab) of follow-up with disease control are not eligible for retreatment.
Subject currently has an ongoing Adverse Event (AE) related to the initial ASP1948 or ASP1948 in combination with nivolumab or pembrolizumab treatment that meets the criteria for treatment interruption or discontinuation.

Frequently Asked Questions

Are clinical trials only for people with advanced cancer?

While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

Will I have to stop my current treatment to participate in a clinical trial?

Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

Should I be worried about getting a placebo?

In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

Do I need a referral from my doctor to take part in a study?

Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

Explore More

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Study summary

Additional Study Details

Study documents

Get more information

Locations

Frequently Asked Questions

Explore More

What are clinical trials?

Why are Clinical Trials Important?

Why Participate in a Clinical Trial?